Almirall acquires rights to new psoriasis drug in Europe

Almirall has entered a commercialization agreement with Danish MC2 Therapeutics, meaning the Spanish dermatology company will take on European sales of MC2's Wynzora cream for treating psoriasis.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

MC2 Therapeutics has sold off the exclusive rights to selling the firm's new cream treating plaque psoriasis in Europe.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading